There is one clinical trial.
This Phase 1/2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Description: Number of participants with a DLT
Measure: Phase 1: Dose Limiting Toxicities (DLT) Time: Up to 28 daysDescription: Number of participants achieving a response per International Working Group (IWG) criteria
Measure: Phase 2: Objective response rate (ORR) Time: Approximately 6 months